


## IN THE CLAIMS

*A listing of the claims presented in this patent application appears below. This listing replaces all prior versions and listing of claims in this patent application.*

1. (Currently Amended) The present invention relates to compounds of formula I:



its enantiomer, diastereomer, or pharmaceutically acceptable salt, hydrate or prodrug thereof wherein:

R<sub>1</sub> and R<sub>2</sub> independently represent


- i) hydrogen,
- ii) (CH<sub>2</sub>)<sub>n</sub>NR<sub>5</sub>R<sub>6</sub>,
- iii) CR<sub>7</sub>R<sub>8</sub>R<sub>9</sub>, C(R)<sub>2</sub>OR<sub>14</sub>, CH<sub>2</sub>NHR<sub>14</sub>,
- iv) C(=O)R<sub>13</sub>, C(=NOH)H, C(=NOR<sub>13</sub>)H, C(=NOR<sub>13</sub>)R<sub>13</sub>, C(=NOH)R<sub>13</sub>, C(=O)N(R<sub>13</sub>)<sub>2</sub>, C(=NOH)N(R<sub>13</sub>)<sub>2</sub>, NHC(=X<sub>1</sub>)N(R<sub>13</sub>)<sub>2</sub>, (C=NH)R<sub>7</sub>, N(R<sub>13</sub>)C(=X<sub>1</sub>)N(R<sub>13</sub>)<sub>2</sub>, COOR<sub>13</sub>, SO<sub>2</sub>R<sub>14</sub>, N(R<sub>13</sub>)SO<sub>2</sub>R<sub>14</sub>, N(R<sub>13</sub>)COR<sub>14</sub>,
- v) (C<sub>1-6</sub>alkyl)CN, CN, CH=C(R)<sub>2</sub>, (CH<sub>2</sub>)<sub>p</sub>OH, C(=O)CHR<sub>13</sub>, C(=NR<sub>13</sub>)R<sub>13</sub>, NR<sub>10</sub>C(=X<sub>1</sub>)R<sub>13</sub>; or

vi) C<sub>5-10</sub> heterocycle optionally substituted with 1-3 groups of R<sub>7</sub>, which may be attached through either a carbon or a heteroatom;

R<sub>1a</sub> represents (CH<sub>2</sub>)<sub>n</sub>NR<sub>5</sub>R<sub>6</sub>, CR<sub>7</sub>R<sub>8</sub>R<sub>9</sub>, C(R)<sub>2</sub>OR<sub>14</sub>, CH<sub>2</sub>NHR<sub>14</sub>,

$C(=O)R_{13}$ ,  $C(=NOH)H$ ,  $C(=NOR_{13})H$ ,  $C(=NOR_{13})R_{13}$ ,  $C(=NOH)R_{13}$ ,  $C(=O)N(R_{13})_2$ ,  
 $C(=NOH)N(R_{13})_2$ ,  $NHC(=X_1)N(R_{13})_2$ ,  $(C=NH)R_7$ ,  $N(R_{13})C(=X_1)N(R_{13})_2$ ,  $COOR_{13}$ ,  $SO_2R_{14}$ ,  
 $N(R_{13})SO_2R_{14}$ ,  $N(R_{13})COR_{14}$ ,  $(C_{1-6}alkyl)CN$ ,  $CN$ ,  $CH=C(R)_2$ ,  $(CH_2)_pOH$ ,  $C(=O)CHR_{13}$ ,  
 $C(=NR_{13})R_{13}$ ,  $NR_{10}C(=X_1)R_{13}$ ; or C5-10 heterocycle optionally substituted with 1-3 groups of  
 $R_7$ , which may be attached through either a carbon or a heteroatom;


X is selected from the group consisting of,



Z represents  $(O)_n$ , H, OH, or halogen;

A represents C (when --- is present provided  $Z = (O)_n$  and  $n=0$ ), C (when --- is not present provided Z is H, OH or halogen), or N (when --- is not present and  $Z = (O)_n$  and  $n=1$ );

--- represents a bond;



represents aryl or heteroaryl, ~~heterocycle, heterocyclyl or heterocyclic,~~  
~~provided that in the case of a heteroaryl, heterocycle, heterocyclyl or heterocyclic,~~ provided that  
in the case of a heteroaryl, a cyclopropyl is not attached to a nitrogen atom on the ring;

$R_x$  represents hydrogen or C<sub>1-6</sub> alkyl;

$R_3$  represent

- i)  $NR_{13}(C=X_2)R_{12}$ ,
- ii)  $NR_{13}(C=X_1)R_{12}$ ,
- iii)  $NR_{13}SO_2R_{14}$ ,
- iv)  $N(R_{13})heteroaryl$ ,

- v)  $\text{NR}_{13}(\text{CHR}_{13})_{0-4}\text{aryl}$ ,
- vi)  $\text{NR}_{13}(\text{CHR}_{13})_{0-4}\text{heteroaryl}$ ,
- vii)  $\text{S}(\text{CHR}_{13})_{0-4}\text{aryl}$ ,
- viii)  $\text{S}(\text{CHR}_{13})_{0-4}\text{heteroaryl}$ ,
- ix)  $\text{O}(\text{CHR}_{13})_{0-4}\text{aryl}$ ,
- x)  $\text{O}(\text{CHR}_{13})_{0-4}\text{heteroaryl}$ ,
- xi)  $\text{NOH}(\text{C}=\text{X}_1)\text{R}_{12}$ ,
- xii)  $-\text{OC}=\text{N}(\text{OCOaryl}) \text{C}_{1-6} \text{ alkyl}$
- xiii)  $-\text{OC}=\text{N}(\text{OH}) \text{C}_{1-6} \text{ alkyl}$
- xiv)  $\text{C}_{5-10} \text{ heteroaryl}$  which may be attached through either a carbon or a heteroatom; said aryl and heteroaryl optionally substituted with 1-3 groups of  $\text{R}_7$ ,

$\text{R}_4$ ,  $\text{R}_{4a}$ ,  $\text{R}_{4b}$ , and  $\text{R}_{4c}$  independently represent

- i) hydrogen,
- ii) halogen,
- iii)  $\text{C}_{1-6}$  alkoxy, or
- iv)  $\text{C}_{1-6}$  alkyl

$r$  and  $s$  independently are 1-3, with the provision that when  $(\text{R}_{4a})_s$  and  $(\text{R}_4)_r$  or  $(\text{R}_{4b})$  and  $(\text{R}_{4c})_s$  are attached to an Ar or HAr ring the sum of  $r$  and  $s$  is less than or equal to 4;

$\text{R}_5$  and  $\text{R}_6$  independently represent

- i) hydrogen,
- ii)  $\text{C}_{1-6}$  alkyl optionally substituted with 1-3 groups of halogen, CN, OH,  $\text{C}_{1-6}$  alkoxy, amino, imino, hydroxyamino, alkoxyamino,  $\text{C}_{1-6}$  acyloxy,  $\text{C}_{1-6}$  alkylsulfenyl,  $\text{C}_{1-6}$  alkylsulfinyl,  $\text{C}_{1-6}$  alkylsulfonyl, aminosulfonyl,  $\text{C}_{1-6}$  alkylaminosulfonyl,  $\text{C}_{1-6}$  dialkylaminosulfonyl, 4-morpholinylsulfonyl, phenyl, pyridine, 5-isoxazolyl, ethylenyloxy, or ethynyl, said phenyl and pyridine optionally substituted with 1-3 halogen, CN, OH,  $\text{CF}_3$ ,  $\text{C}_{1-6}$  alkyl or  $\text{C}_{1-6}$  alkoxy;
- iii)  $\text{C}_{1-6}$  acyl optionally substituted with 1-3 groups of halogen, OH, SH,  $\text{C}_{1-6}$  alkoxy, naphthalenoxy, phenoxy, amino,  $\text{C}_{1-6}$  acylamino, hydroxylamino, alkoxyamino,  $\text{C}_{1-6}$  acyloxy, aralkyloxy, phenyl, pyridine,  $\text{C}_{1-6}$  alkylcarbonyl,  $\text{C}_{1-6}$  alkylamino,  $\text{C}_{1-6}$  dialkylamino,  $\text{C}_{1-6}$  hydroxyacyloxy,  $\text{C}_{1-6}$  alkylsulfenyl, phthalimido, maleimido,

- succinimido, said phenoxy, phenyl and pyridine optionally substituted with 1-3 groups of halo, OH, CN, C<sub>1-6</sub> alkoxy, amino, C<sub>1-6</sub> acylamino, CF<sub>3</sub> or C<sub>1-6</sub> alkyl;
- iv) C<sub>1-6</sub> alkylsulfonyl optionally substituted with 1-3 groups of halogen, OH, C<sub>1-6</sub> alkoxy, amino, hydroxylamino, alkoxylamino, C<sub>1-6</sub> acyloxy, or phenyl; said phenyl optionally substituted with 1-3 groups of halo, OH, C<sub>1-6</sub> alkoxy, amino, C<sub>1-6</sub> acylamino, CF<sub>3</sub> or C<sub>1-6</sub> alkyl;
  - v) arylsulfonyl optionally substituted with 1-3 of halogen, C<sub>1-6</sub> alkoxy, OH or C<sub>1-6</sub> alkyl;
  - vi) C<sub>1-6</sub> alkoxycarbonyl optionally substituted with 1-3 of halogen, OH, C<sub>1-6</sub> alkoxy, C<sub>1-6</sub> acyloxy, or phenyl, said phenyl optionally substituted with 1-3 groups of halo, OH, C<sub>1-6</sub> alkoxy, amino, C<sub>1-6</sub> acylamino, CF<sub>3</sub> or C<sub>1-6</sub> alkyl;
  - vii) aminocarbonyl, C<sub>1-6</sub> alkylaminocarbonyl or C<sub>1-6</sub> dialkylaminocarbonyl, said alkyl groups optionally substituted with 1-3 groups of halogen, OH, C<sub>1-6</sub> alkoxy or phenyl
  - viii) five to six membered heterocycles optionally substituted with 1-3 groups of halogen, OH, CN, amino, C<sub>1-6</sub> acylamino, C<sub>1-6</sub> alkylsulfonylamino, C<sub>1-6</sub> alkoxycarbonylamino, C<sub>1-6</sub> alkoxy, C<sub>1-6</sub> acyloxy or C<sub>1-6</sub> alkyl, said alkyl optionally substituted with 1-3 groups of halogen, or C<sub>1-6</sub> alkoxy;
  - ix) C<sub>3-6</sub> cycloalkylcarbonyl optionally substituted with 1-3 groups of halogen, OH, C<sub>1-6</sub> alkoxy or CN;
  - x) benzoyl optionally substituted with 1-3 groups of halogen, OH, C<sub>1-6</sub> alkoxy, C<sub>1-6</sub> alkyl, CF<sub>3</sub>, C<sub>1-6</sub> alkanoyl, amino or C<sub>1-6</sub> acylamino;
  - xi) pyrrolylcarbonyl optionally substituted with 1-3 of C<sub>1-6</sub> alkyl;
  - xii) C<sub>1-2</sub> acyloxyacetyl where the acyl is optionally substituted with amino, C<sub>1-6</sub> alkylamino, C<sub>1-6</sub> dialkylamino, 4-morpholino, 4-aminophenyl, 4-(dialkylamino)phenyl, 4-(glycylamino)phenyl; or

R<sub>5</sub> and R<sub>6</sub> taken together with any intervening atoms can form a 3 to 7 membered heterocyclic ring containing carbon atoms and 1-2 heteroatoms independently chosen from O, S, SO, SO<sub>2</sub>, N, or NR<sub>8</sub>;

R<sub>7</sub> represent

- i) hydrogen, halogen, CN, CO<sub>2</sub>R, CON(R)<sub>2</sub>, CHO, (CH<sub>2</sub>)<sub>0-3</sub>NHAc, C(=NOR), OH, C<sub>1-6</sub> alkoxy, C<sub>1-6</sub> alkyl, alkenyl, hydroxy C<sub>1-6</sub> alkyl, (CH<sub>2</sub>)<sub>1-3</sub>NHC(O)C<sub>1-6</sub> alkyl, (CH<sub>2</sub>)<sub>0-3</sub>N(C<sub>1-6</sub> alkyl)<sub>2</sub>
- ii) (CH<sub>2</sub>)<sub>n</sub>amino, (CH<sub>2</sub>)<sub>n</sub>C<sub>1-6</sub> alkylamino, C<sub>1-6</sub> dialkylamino, hydroxylamino or C<sub>1-2</sub> alkoxyamino all of which can be optionally substituted on the nitrogen with C<sub>1-6</sub> acyl,

C<sub>1-6</sub> alkylsulfonyl or C<sub>1-6</sub> alkoxycarbonyl, said acyl and alkylsulfonyl optionally substituted with 1-2 of halogen or OH;

R<sub>8</sub> and R<sub>9</sub> independently represents

- i) H, CN,
- ii) C<sub>1-6</sub> alkyl optionally substituted with 1-3 halogen, CN, OH, C<sub>1-6</sub> alkoxy, C<sub>1-6</sub> acyloxy, or amino,
- iii) phenyl optionally substituted with 1-3 groups of halogen, OH, C<sub>1-6</sub> alkoxy; or

R<sub>7</sub> and R<sub>8</sub> taken together can form a 3-7 membered carbon ring optionally interrupted with 1-2 heteroatoms chosen from O, S, SO, SO<sub>2</sub>, NH, and NR<sub>8</sub>;

X<sub>1</sub> represents O, S or NR<sub>13</sub>, NCN, NCO<sub>2</sub>R<sub>16</sub>, or NSO<sub>2</sub>R<sub>14</sub>

X<sub>2</sub> represents O, S, NH or NSO<sub>2</sub>R<sub>14</sub>;

R<sub>10</sub> represents hydrogen, C<sub>1-6</sub> alkyl or CO<sub>2</sub>R<sub>15</sub>;

R<sub>12</sub> represents hydrogen, C<sub>1-6</sub> alkyl, NH<sub>2</sub>, OR, CHF<sub>2</sub>, CHCl<sub>2</sub>, CR<sub>2</sub>Cl, (CH<sub>2</sub>)<sub>n</sub>SR, (CH<sub>2</sub>)<sub>n</sub>CN, (CH<sub>2</sub>)<sub>n</sub>SO<sub>2</sub>R, (CH<sub>2</sub>)<sub>n</sub>S(O)R, C<sub>1-6</sub> alkylamino, C<sub>5-10</sub> heteroaryl or C<sub>1-6</sub> dialkylamino, where said alkyl may be substituted with 1-3 groups of halo, CN, OH or C<sub>1-6</sub> alkoxy, said heteroaryl optionally substituted with 1-3 groups of R<sub>7</sub>;

Each R<sub>13</sub> represents independently hydrogen, C<sub>1-6</sub> alkyl, C<sub>6-10</sub> aryl, NR<sub>5</sub>R<sub>6</sub>, SR<sub>8</sub>, S(O)R<sub>8</sub>, S(O)<sub>2</sub>R<sub>8</sub>, CN, OH, C<sub>1-6</sub> alkylS(O)R, C<sub>1-6</sub> alkoxycarbonyl, hydroxycarbonyl, -OCOaryl, C<sub>1-6</sub> acyl, C<sub>3-7</sub> membered carbon ring optionally interrupted with 1-4 heteroatoms chosen from O, S, SO, SO<sub>2</sub>, NH and NR<sub>8</sub> where said C<sub>1-6</sub> alkyl, aryl or C<sub>1-6</sub> acyl groups may be independently substituted with 0-3 halogens, hydroxy, N(R)<sub>2</sub>, CO<sub>2</sub>R, C<sub>6-10</sub> aryl, C<sub>5-10</sub> heteroaryl, or C<sub>1-6</sub> alkoxy groups;

When two R<sub>13</sub> groups are attached to the same atom or two adjacent atoms they may be taken together to form a 3-7 membered carbon ring optionally interrupted with 1-2 heteroatoms chosen from O, S, SO, SO<sub>2</sub>, NH, and NR<sub>8</sub>;

R represents hydrogen or C<sub>1-6</sub> alkyl;

R<sub>14</sub> represents amino, C<sub>1-6</sub> alkyl, C<sub>1-6</sub> haloalkyl, five to six membered heterocycles or phenyl, said phenyl and heterocycles optionally substituted with 1-3 group of halo, C<sub>1-6</sub> alkoxy, C<sub>1-6</sub> acylamino, or C<sub>1-6</sub> alkyl, hydroxy and/or amino, said amino and hydroxy optionally protected with an amino or hydroxy protecting group;



R<sub>15</sub> is C<sub>1-6</sub> alkyl or benzyl said benzyl optionally substituted with 1-3 groups of halo, OH, C<sub>1-6</sub> alkoxy, amino, C<sub>1-6</sub> acylamino, or C<sub>1-6</sub> alkyl;


R<sub>16</sub> is hydrogen, C<sub>5-10</sub>heteroaryl, C<sub>6-10</sub>aryl, said heteroaryl and aryl optionally substituted with 1-3 groups of R<sub>7</sub>;

p represents 0-2 and


n represents 0-1.

2. (Original) A compound according to claim 1 wherein R<sub>1</sub> and R<sub>2</sub> independently represent H, NR<sub>5</sub>R<sub>6</sub>, CN, OH, C(R)<sub>2</sub>OR<sub>14</sub>, NHC(=X<sub>1</sub>)N(R<sub>13</sub>)<sub>2</sub>, C(=NOH)N(R<sub>13</sub>)<sub>2</sub>, NR<sub>10</sub>C(=X<sub>1</sub>)R<sub>13</sub> or CR<sub>7</sub>R<sub>8</sub>R<sub>9</sub> and R<sub>1a</sub> represents NR<sub>5</sub>R<sub>6</sub>, CN, OH, C(R)<sub>2</sub>OR<sub>14</sub>, NHC(=X<sub>1</sub>)N(R<sub>13</sub>)<sub>2</sub>, C(=NOH)N(R<sub>13</sub>)<sub>2</sub>, NR<sub>10</sub>C(=X<sub>1</sub>)R<sub>13</sub> or CR<sub>7</sub>R<sub>8</sub>R<sub>9</sub>.

3. (Original) A compound according to claim 2 wherein  and  independently are phenyl, pyridine, pyrimidine, or piperidine.

4. (Original) A compound according to claim 3 wherein when X is .

5. (Original) A compound according to claim 3 wherein X is




6. (Original) A compound according to claim 5 wherein A is C, --- is present and  $Z=(O)_n$  where  $n=0$ , A is C, --- is not present and  $Z=H$ , OH or halogen, or A is N, --- is not present and  $Z=(O)_n$  where  $n=1$ .


7. (Original) A compound according to claim 6 wherein one of  $R_1$  and  $R_2$  is H and the other is  $NR_5R_6$ , or H and the other is  $NR_{10}C(=X_1)R_{13}$

8. (Original) A compound according to claim 4 wherein one of  $R_{1a}$  is CN,  $NR_{10}C(=X_1)R_{13}$ , or  $NR_5R_6$ .

9. (Original) A compound according to claim 1 wherein  $R_3$  is  $NR(C=X_1)R_{12}$ , C5-10 heteroaryl,  $NH(CH_2)_{0-4}$ aryl,  $NH(CH_2)_{0-4}$ heteroaryl, said aryl and heteroaryl optionally substituted with 1-3 groups of  $R_a$ .

10. (Original) A compound according to claim 9 wherein  $R_3$  is a C5-10 heteroaryl represented by  which represents an optionally substituted aromatic heterocyclic group containing 1 to 4 nitrogen atoms and at least one double bond, and which is connected through a bond on any nitrogen.


11. (Original) A compound according to claim 1 wherein the structural formula is II:



Formula II

Wherein:

X is selected from the group consisting of,



Z represents  $(O)_n$ , H, OH, or halogen;

A represents C (when --- is present provided  $Z = (O)_n$  and  $n=0$ ), C (when --- is not present provided Z is H, OH or halogen), or N (when --- is not present and  $Z = (O)_n$  and  $n=1$ ); and  $R_{1a}$ ,  $R_1$ ,  $R_2$ ,  $R_x$ ,  $R_4$ ,  $R_{4a}$ , and  $R_3$  are as previously described herein.

12. (Original) A compound according to claim 11 wherein  $R_{1a}$  is CN or  $NR_5R_6$ .

13. (Original) A compound which is:  
 N-[5(S)-3-[4-[2-(1-cyanocyclopropan-1-yl)pyridin-5-yl]phenyl]-2-oxooxazolidin-5-ylmethyl]acetamide,  
 N-[5(S)-3-[4-[5-(1-cyanocyclopropan-1-yl)pyridin-2-yl]phenyl]-2-oxooxazolidin-5-ylmethyl]acetamide,  
 N-[5(S)-3-[4-[2-(1-cyanocyclopropan-1-yl)pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]acetamide,  
 N-[5(S)-3-[4-[2-(1-(t-butoxycarbonyl)aminocyclopropan-1-yl)pyridin-5-yl]phenyl]-2-oxooxazolidin-5-ylmethyl]acetamide,  
 N-[5(S)-3-[4-[2-(1-aminocyclopropan-1-yl)pyridin-5-yl]phenyl]-2-oxooxazolidin-5-ylmethyl]acetamide,  
 N-[5(S)-3-[4-[2-(1-(t-butoxycarbonyl)aminocyclopropan-1-yl)pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]acetamide,  
 N-[5(S)-3-[4-[2-(1-aminocyclopropan-1-yl)pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]acetamide,  
 N-[5(S)-3-[4-[2-(1-(dimethylamino)methylcyclopropan-1-yl)pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]acetamide,  
 N-[5(S)-3-[4-[2-(1-(dimethylamino)methylcyclopropan-1-yl)pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]acetamide,  
 N-[5(S)-3-[4-[2-(1-t-butoxycarbonylcyclopropan-1-yl)pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]acetamide,



N-[5(S)-3-[4-[2-(1-hydroxymethylcyclopropan-1-yl)pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]acetamide,  
 N-[5(S)-3-[4-[2-(1-hydroxycarbonylcyclopropan-1-yl)pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]acetamide hydrochloride,  
 N-[5(S)-3-[4-[2-(1-(t-butoxycarbonyl)aminocyclopropan-1-yl)pyridin-5-yl]-3,5-difluorophenyl]-2-oxooxazolidin-5-ylmethyl]acetamide,  
 N-[5(S)-3-[4-[2-(1-aminocyclopropan-1-yl)pyridin-5-yl]-3,5-difluorophenyl]-2-oxooxazolidin-5-ylmethyl]acetamide,  
 N-[5(S)-3-[4-[2-(1-aminomethylcyclopropan-1-yl)pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]acetamide,  
 1-[5(R)-3-[4-[2-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-6-(N-t-butoxycarbonyl)amino-3-azabicyclo[3.1.0]hexan-3-yl]pyridyl-5-yl]phenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole,  
 1-[5(R)-3-[4-[2-(1-aminocyclopropan-1-yl)pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole,  
 1-[5(R)-3-[4-[2-(1-aminocyclopropan-1-yl)pyridin-5-yl]phenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole,  
 1-[5(R)-3-[4-[2-(1-cyanocyclopropan-1-yl)pyridin-5-yl]phenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole,  
 1-[5(R)-3-[4-[2-(1-cyanocyclopropan-1-yl)pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole,  
 N-[5(R)-3-[4-[2-(1-cyanocyclopropan-1-yl)pyridin-5-yl]-3,5-difluorophenyl]-2-oxooxazolidin-5-ylmethyl]acetamide,  
 5(R)-3-[4-[2-(1-cyanocyclopropan-1-yl)pyridin-5-yl]phenyl]-5-[(isoxazol-3-yl)oxy]methyloxazolidin-2-one,  
 5(R)-3-[4-[2-(1-cyanocyclopropan-1-yl)pyridin-5-yl]phenyl]-5-[N-(t-butoxycarbonyl)-N-(isoxazol-3-yl)]aminomethyloxazolidin-2-one,  
 5(R)-3-[4-[2-(1-cyanocyclopropan-1-yl)pyridin-5-yl]phenyl]-5-[N-(isoxazol-3-yl)]aminomethyloxazolidin-2-one,  
 5(R)-3-[4-[2-(1-t-butoxycarbonylaminocyclopropan-1-yl)pyridin-5-yl]-3-fluorophenyl]-5-[N-(t-butoxycarbonyl)-N-(isoxazol-3-yl)]aminomethyloxazolidin-2-one,  
 5(R)-3-[4-[2-(1-aminocyclopropan-1-yl)pyridin-5-yl]-3-fluorophenyl]-5-[N-(t-butoxycarbonyl)-N-(isoxazol-3-yl)]aminomethyloxazolidin-2-one,  
 5(R)-3-[4-[2-(1-t-butoxycarbonylaminocyclopropan-1-yl)pyridin-5-yl]phenyl]-5-[(isoxazol-3-yl)oxy]methyloxazolidin-2-one,

5(R)-3-[4-[2-(1-aminocyclopropan-1-yl)pyridin-5-yl]phenyl]-5-[(isoxazol-3-yl)oxy]methyloxazolidin-2-one,  
 5(R)-3-[4-[2-(1-cyanocyclopropan-1-yl)pyridin-5-yl]-3-fluorophenyl]-5-[N-(t-butoxycarbonyl)-N-(isoxazol-3-yl)]aminomethyloxazolidin-2-one,  
 5(R)-3-[4-[2-(1-cyanocyclopropan-1-yl)pyridin-5-yl]-3-fluorophenyl]-5-[N-(isoxazol-3-yl)]aminomethyloxazolidin-2-one,  
 5(R)-3-[4-[2-(1-cyanocyclopropan-1-yl)pyridin-5-yl]-3-fluorophenyl]-5-[(isoxazol-3-yl)oxy]methyloxazolidin-2-one,  
 1-[5(R)-3-[4-[2-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-6-(N-t-butoxycarbonyl)amino-3-azabicyclo[3.1.0]hexan-3-yl]pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole, 1-[5(R)-3-[4-[2-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-6-amino-3-azabicyclo[3.1.0]hexan-3-yl]pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole,  
 5(R)-3-[4-[2-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-6-(N-t-butoxycarbonyl)amino-3-azabicyclo[3.1.0]hexan-3-yl]pyridin-5-yl]phenyl]-2-oxooxazolidin-5-ylmethyl]acetamide,  
 5(R)-3-[4-[2-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-6-amino-3-azabicyclo[3.1.0]hexan-3-yl]pyridin-5-yl]phenyl]-2-oxooxazolidin-5-ylmethyl]acetamide,  
 5(R)-3-[4-[2-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-6-(N-t-butoxycarbonyl)amino-3-azabicyclo[3.1.0]hexan-3-yl]pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]acetamide,  
 5(R)-3-[4-[2-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-6-amino-3-azabicyclo[3.1.0]hexan-3-yl]pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]acetamide,  
 1-[5(R)-3-[4-[2-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-6-amino-3-azabicyclo[3.1.0]hexan-3-yl]pyridin-5-yl]phenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole,  
 1-[5(R)-3-[4-[2-(1-t-butoxycarbonylaminocyclopropan-1-yl)pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]-4-methyl-1,2,3-triazole,  
 1-[5(R)-3-[4-[2-(1-aminocyclopropan-1-yl)pyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]-4-methyl-1,2,3-triazole,  
 N-[5(S)-3-[4-[4-(1-(t-butoxycarbonyl)aminocyclopropan-1-yl)phenyl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]acetamide,  
 N-[5(S)-3-[4-[4-(1-aminocyclopropan-1-yl)phenyl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]acetamide,  
 N-[5(S)-3-[4-[4-(1-(t-butoxycarbonyl)aminocyclopropan-1-yl)phenyl]phenyl]-2-oxooxazolidin-5-ylmethyl]acetamide,  
 N-[5(S)-3-[4-[4-(1-aminocyclopropan-1-yl)phenyl]phenyl]-2-oxooxazolidin-5-ylmethyl]acetamide,  
 N-[5(S)-3-[4-[4-(1-(t-butoxycarbonyl)aminocyclopropan-1-yl)-3-fluorophenyl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]acetamide,

N-[5(S)-3-[4-[4-(1-aminocyclopropan-1-yl)-3-fluorophenyl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]acetamide,  
 N-[5(S)-3-[4-[4-(1-(t-butoxycarbonyl)aminocyclopropan-1-yl)-3-fluorophenyl]phenyl]-2-oxooxazolidin-5-ylmethyl]acetamide,  
 N-[5(S)-3-[4-[4-(1-aminocyclopropan-1-yl)-3-fluorophenyl]phenyl]-2-oxooxazolidin-5-ylmethyl]acetamide,  
 N-[5(S)-3-[4-[2-(1-aminocyclopropan-1-yl)-3-fluoropyridin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]acetamide,  
 N-[5(S)-3-[4-[4-(1-aminocyclopropan-1-yl)phenyl]-3,5-difluorophenyl]-2-oxooxazolidin-5-ylmethyl]acetamide,  
 N-[5(S)-3-[4-[2-(1-aminocyclopropan-1-yl)pyrimidin-5-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]acetamide,  
 1-[5(R)-3-[4-[2-(1-aminocyclopropan-1-yl)pyridin-5-yl]-3,5-difluorophenyl]-2-oxooxazolidin-5-ylmethyl]-4-methyl-1,2,3-triazole,  
 1-[5(R)-3-[4-[2-(1-aminocyclopropan-1-yl)-3-fluoropyridin-5-yl]-3,5-difluorophenyl]-2-oxooxazolidin-5-ylmethyl]-4-methyl-1,2,3-triazole,  
 1-[5(R)-3-[4-[2-(1-aminocyclopropan-1-yl)pyridin-5-yl]-3,5-difluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole,  
 or

its enantiomer, diastereomer, or pharmaceutically acceptable salt, hydrate or prodrug thereof.

14. (Original) A pharmaceutical composition comprised of a compound in accordance with claim 1 in combination with a pharmaceutically acceptable carrier and optionally a in combination with a vitamin selected from the group consisting vitamin B2, vitamin B6, vitamin B12 and folic acid.

15. (Original) A method of treating or preventing a bacterial infection in a mammalian patient in need thereof, comprising administering to said patient an effective amount of a compound of claim 1.

16. (Original) A method of treating or preventing bacterial infection or an oxazolidinone-associated side effect by administering an effective amount of a compound of formula I of claim 1 and an effective amount of one or more of a vitamin selected from the group consisting of vitamin B2, vitamin B6, vitamin B12 and folic acid to a patient in need thereof.

17. (Original) A method according to claim 16 for treating or preventing oxazolidinone-associated normocytic anemia, peripheral sensory neuropathy, sideroblastic anemia, peripheral sensory neuropathy, optic neuropathy, seizures, thrombocytopenia, cheilosis,

hypo-regenerative anemia, megaloblastic anemia and seborrheic dermatitis by administering an effective amount of vitamin B2 to a patient in need thereof.